Figure 3. Autophagic response to treatment predicts improved outcome following pre-operative Gemcitabine/HCQ.
LC3 punctate staining was evaluated by immunoflourescence in circulating peripheral blood mononuclear cells (PBMCs) before and after treatment (a). Patients with a greater than 51% increase in LC3 puncta (LC3-II Response) had improved disease free (b) and overall survival (c).